Clinical and device-related characteristics of the study population and of patients with complications occurring after the 3 month FU
| . | All patients ( n = 618) . | Patients with complications > 3 month FU ( n = 110) . | P -value . |
|---|---|---|---|
| Age (years) | 60 ± 12.5 | 58 ± 12.9 | NS |
| Male | 505 (82%) | 88 (80%) | NS |
| EF (%) | 37.2 ± 13.2 | 38.3 ± 13.1 | NS |
| Underlying heart disease | NS | ||
| Coronary artery disease | 370 (59.9%) | 58 (52.7%) | |
| Idiopathic dilated cardiomyopathy | 133 (21.5%) | 26 (23.6%) | |
| Others | 69 (11.3%) | 18 (16.4%) | |
| No structural heart disease | 45 (7.3%) | 8 (7.3%) | |
| Prior myocardial infarction | 289 (47%) | 48 (43.6%) | NS |
| NYHA class | NS | ||
| I + II | 397 (64%) | 71 (64.5%) | |
| III + IV | 221 (36%) | 39 (35.5%) | |
| LV aneurysm | 97 (15.7%) | 14 (12.7%) | NS |
| Prior coronary bypass surgery | 107 (17.3%) | 17 (15.5%) | NS |
| Underlying rhythm | 0.004 | ||
| Sinus rhythm | 512 (83%) | 83 (75.6%) | |
| Atrial fibrillation | 50 (8%) | 8 (7.3%) | |
| Paced rhythm | 56 (9%) | 19 (17.3%) | |
| Concomitant antiarrhythmic drugs | |||
| At implantation | 161 (26%) | 43 (39%) | 0.001 |
| During FU a | 101 (16%) | 18 (16%) | NS |
| Indication for ICD implantation | 0.014 | ||
| Primary prevention | 132 (21.4%) | 14 (12.7%) | |
| Secondary prevention | 483 (78.6%) | 96 (87.3%) | |
| Unplanned visitsa | 258 (41.7%) | 63 (57.3%) | <0.001 |
| Device location | <0.001 | ||
| Pectoral | 481 (77.8%) | 59 (53.6%) | |
| Abdominal | 137 (22.2%) | 51 (46.4%) | |
| “Cold can” system | 126 (20.4%) | 47 (42.7%) | <0.001 |
| Date of implant | <0.001 | ||
| 1986–1995 | 217 (35.1%) | 67 (61%) | |
| 1996–1998 | 181 (29.3%) | 32 (29%) | |
| 1999–2002 | 220 (35.6%) | 11 (10%) |
| . | All patients ( n = 618) . | Patients with complications > 3 month FU ( n = 110) . | P -value . |
|---|---|---|---|
| Age (years) | 60 ± 12.5 | 58 ± 12.9 | NS |
| Male | 505 (82%) | 88 (80%) | NS |
| EF (%) | 37.2 ± 13.2 | 38.3 ± 13.1 | NS |
| Underlying heart disease | NS | ||
| Coronary artery disease | 370 (59.9%) | 58 (52.7%) | |
| Idiopathic dilated cardiomyopathy | 133 (21.5%) | 26 (23.6%) | |
| Others | 69 (11.3%) | 18 (16.4%) | |
| No structural heart disease | 45 (7.3%) | 8 (7.3%) | |
| Prior myocardial infarction | 289 (47%) | 48 (43.6%) | NS |
| NYHA class | NS | ||
| I + II | 397 (64%) | 71 (64.5%) | |
| III + IV | 221 (36%) | 39 (35.5%) | |
| LV aneurysm | 97 (15.7%) | 14 (12.7%) | NS |
| Prior coronary bypass surgery | 107 (17.3%) | 17 (15.5%) | NS |
| Underlying rhythm | 0.004 | ||
| Sinus rhythm | 512 (83%) | 83 (75.6%) | |
| Atrial fibrillation | 50 (8%) | 8 (7.3%) | |
| Paced rhythm | 56 (9%) | 19 (17.3%) | |
| Concomitant antiarrhythmic drugs | |||
| At implantation | 161 (26%) | 43 (39%) | 0.001 |
| During FU a | 101 (16%) | 18 (16%) | NS |
| Indication for ICD implantation | 0.014 | ||
| Primary prevention | 132 (21.4%) | 14 (12.7%) | |
| Secondary prevention | 483 (78.6%) | 96 (87.3%) | |
| Unplanned visitsa | 258 (41.7%) | 63 (57.3%) | <0.001 |
| Device location | <0.001 | ||
| Pectoral | 481 (77.8%) | 59 (53.6%) | |
| Abdominal | 137 (22.2%) | 51 (46.4%) | |
| “Cold can” system | 126 (20.4%) | 47 (42.7%) | <0.001 |
| Date of implant | <0.001 | ||
| 1986–1995 | 217 (35.1%) | 67 (61%) | |
| 1996–1998 | 181 (29.3%) | 32 (29%) | |
| 1999–2002 | 220 (35.6%) | 11 (10%) |
a Only unplanned visits/antiarrhythmic prescriptions prior to complications were evaluated.
Clinical and device-related characteristics of the study population and of patients with complications occurring after the 3 month FU
| . | All patients ( n = 618) . | Patients with complications > 3 month FU ( n = 110) . | P -value . |
|---|---|---|---|
| Age (years) | 60 ± 12.5 | 58 ± 12.9 | NS |
| Male | 505 (82%) | 88 (80%) | NS |
| EF (%) | 37.2 ± 13.2 | 38.3 ± 13.1 | NS |
| Underlying heart disease | NS | ||
| Coronary artery disease | 370 (59.9%) | 58 (52.7%) | |
| Idiopathic dilated cardiomyopathy | 133 (21.5%) | 26 (23.6%) | |
| Others | 69 (11.3%) | 18 (16.4%) | |
| No structural heart disease | 45 (7.3%) | 8 (7.3%) | |
| Prior myocardial infarction | 289 (47%) | 48 (43.6%) | NS |
| NYHA class | NS | ||
| I + II | 397 (64%) | 71 (64.5%) | |
| III + IV | 221 (36%) | 39 (35.5%) | |
| LV aneurysm | 97 (15.7%) | 14 (12.7%) | NS |
| Prior coronary bypass surgery | 107 (17.3%) | 17 (15.5%) | NS |
| Underlying rhythm | 0.004 | ||
| Sinus rhythm | 512 (83%) | 83 (75.6%) | |
| Atrial fibrillation | 50 (8%) | 8 (7.3%) | |
| Paced rhythm | 56 (9%) | 19 (17.3%) | |
| Concomitant antiarrhythmic drugs | |||
| At implantation | 161 (26%) | 43 (39%) | 0.001 |
| During FU a | 101 (16%) | 18 (16%) | NS |
| Indication for ICD implantation | 0.014 | ||
| Primary prevention | 132 (21.4%) | 14 (12.7%) | |
| Secondary prevention | 483 (78.6%) | 96 (87.3%) | |
| Unplanned visitsa | 258 (41.7%) | 63 (57.3%) | <0.001 |
| Device location | <0.001 | ||
| Pectoral | 481 (77.8%) | 59 (53.6%) | |
| Abdominal | 137 (22.2%) | 51 (46.4%) | |
| “Cold can” system | 126 (20.4%) | 47 (42.7%) | <0.001 |
| Date of implant | <0.001 | ||
| 1986–1995 | 217 (35.1%) | 67 (61%) | |
| 1996–1998 | 181 (29.3%) | 32 (29%) | |
| 1999–2002 | 220 (35.6%) | 11 (10%) |
| . | All patients ( n = 618) . | Patients with complications > 3 month FU ( n = 110) . | P -value . |
|---|---|---|---|
| Age (years) | 60 ± 12.5 | 58 ± 12.9 | NS |
| Male | 505 (82%) | 88 (80%) | NS |
| EF (%) | 37.2 ± 13.2 | 38.3 ± 13.1 | NS |
| Underlying heart disease | NS | ||
| Coronary artery disease | 370 (59.9%) | 58 (52.7%) | |
| Idiopathic dilated cardiomyopathy | 133 (21.5%) | 26 (23.6%) | |
| Others | 69 (11.3%) | 18 (16.4%) | |
| No structural heart disease | 45 (7.3%) | 8 (7.3%) | |
| Prior myocardial infarction | 289 (47%) | 48 (43.6%) | NS |
| NYHA class | NS | ||
| I + II | 397 (64%) | 71 (64.5%) | |
| III + IV | 221 (36%) | 39 (35.5%) | |
| LV aneurysm | 97 (15.7%) | 14 (12.7%) | NS |
| Prior coronary bypass surgery | 107 (17.3%) | 17 (15.5%) | NS |
| Underlying rhythm | 0.004 | ||
| Sinus rhythm | 512 (83%) | 83 (75.6%) | |
| Atrial fibrillation | 50 (8%) | 8 (7.3%) | |
| Paced rhythm | 56 (9%) | 19 (17.3%) | |
| Concomitant antiarrhythmic drugs | |||
| At implantation | 161 (26%) | 43 (39%) | 0.001 |
| During FU a | 101 (16%) | 18 (16%) | NS |
| Indication for ICD implantation | 0.014 | ||
| Primary prevention | 132 (21.4%) | 14 (12.7%) | |
| Secondary prevention | 483 (78.6%) | 96 (87.3%) | |
| Unplanned visitsa | 258 (41.7%) | 63 (57.3%) | <0.001 |
| Device location | <0.001 | ||
| Pectoral | 481 (77.8%) | 59 (53.6%) | |
| Abdominal | 137 (22.2%) | 51 (46.4%) | |
| “Cold can” system | 126 (20.4%) | 47 (42.7%) | <0.001 |
| Date of implant | <0.001 | ||
| 1986–1995 | 217 (35.1%) | 67 (61%) | |
| 1996–1998 | 181 (29.3%) | 32 (29%) | |
| 1999–2002 | 220 (35.6%) | 11 (10%) |
a Only unplanned visits/antiarrhythmic prescriptions prior to complications were evaluated.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
